Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +65

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Dividend AI-generated analysis

📈 Abbott Laboratories reported second-quarter sales of $12.59 billion, representing a 13% increase on a reported basis and a 4.8% comparable rise.

💊 The Medical Devices segment generated $5.85 billion in sales, growing 8.4% on a comparable basis with strong performance in Electrophysiology.

🔬 Diagnostics sales reached $3.09 billion, surging 42.3% on a reported basis driven by the integration of Exact Sciences and growth in Cancer Diagnostics.

💰 Abbott raised its quarterly dividend to $0.63 per share for 2026, marking its 54th consecutive year of dividend increases.

📈 Management upgraded full-year adjusted EPS guidance to $5.45-$5.60 while maintaining a comparable sales growth outlook of 6.5%-7.5%.

⚠️ Nutrition sales declined 3.6% on a comparable basis in the second quarter, contributing to uneven growth across the broad portfolio.

📉 Rapid and Molecular Diagnostics fell 8.0%, partly due to lower respiratory-virus testing sales volumes.

💸 Intangible amortization expenses increased to $658 million in Q2 following the Exact Sciences acquisition, impacting GAAP EPS.

🏥 The company expects sales and earnings growth to accelerate in the second half of the year to meet full-year targets.

🔍 Abbott offers a diversified risk profile compared to peers like Gilead, which relies heavily on its HIV franchise for revenue.

Bullish Signals
  • Abbott Laboratories reported strong second-quarter sales growth of 13% to $12.59 billion, demonstrating robust business momentum.
  • The Medical Devices segment grew 8.4% on a comparable basis, with specific double-digit growth in Electrophysiology and Rhythm Management areas.
  • Diagnostics sales surged 42.3% to $3.09 billion, driven by successful integration of Exact Sciences and growth in Cancer Diagnostics.
  • Abbott raised its quarterly dividend by 6.8% to $0.63 per share for 2026, extending its streak of 54 consecutive years of dividend increases.
  • The company upgraded its full-year adjusted EPS guidance to $5.45-$5.60, reflecting confidence in future performance.
  • Management maintains a comparable sales growth outlook of 6.5%-7.5%, anticipating acceleration in the second half of the year.
Risk Factors
  • Nutrition sales declined 3.6% on a comparable basis during fiscal Q2, highlighting uneven growth within the broad portfolio.
  • Rapid and Molecular Diagnostics fell 8.0%, partly reflecting lower respiratory-virus testing sales volumes.
  • Intangible amortization expenses increased to $658 million in Q2 following the Exact Sciences acquisition, impacting GAAP EPS significantly.
  • There is a gap between current Q2 comparable sales growth of 4.8% and the full-year target range of 6.5%-7.5%.
Full Analysis
Abbott Laboratories (NYSE:ABT) reported strong second-quarter results with total sales increasing 13% to $12.59 billion and adjusted EPS rising 4% to $1.31. The company's Medical Devices segment, its largest business, grew 8.4% on a comparable basis, driven by double-digit growth in Electrophysiology and Rhythm Management. Additionally, the acquisition of Exact Sciences has successfully integrated into the portfolio, with Diagnostics sales surging 42.3% to $3.09 billion, largely fueled by growth in Cancer Diagnostics. Abbott continues its robust track record as a dividend aristocrat, having increased its quarterly dividend for 54 consecutive years. For fiscal year 2026, the company raised its quarterly dividend by 6.8% to $0.63 per share and upgraded its full-year adjusted EPS guidance to a range of $5.45-$5.60. Management maintains a comparable sales growth outlook of 6.5%-7.5%, anticipating acceleration in the second half of the year despite some headwinds in Nutrition and Molecular Diagnostics segments. The article contrasts Abbott's diversified profile with Gilead Sciences, noting that while Gilead shows stronger current momentum, it faces concentration risk from its HIV franchise which accounts for roughly three-quarters of product revenue. Abbott's strategy involves spreading risk across medical devices, diagnostics, nutrition, and pharmaceuticals, though it faces specific challenges such as lower respiratory-virus testing sales and higher intangible amortization costs following the Exact Sciences acquisition.